Watchlist Price Alert

Rhythm Pharmaceuticals In... (RYTM)

NASDAQ: RYTM · Real-Time Price · USD

64.56

1.85 (2.95%)

At close: May 07, 2025, 3:59 PM

64.63

0.11%

After-hours: May 07, 2025, 05:52 PM EDT

2.95% (1D)

Bid	59.85
Market Cap	4.1B
Revenue (ttm)	130.13M
Net Income (ttm)	-261.89M
EPS (ttm)	-4.34
PE Ratio (ttm)	-14.88
Forward PE	-47.08
Analyst	Strong Buy

Ask	65.88
Volume	865,130
Avg. Volume (20D)	682,610
Open	61.07
Previous Close	62.71
Day's Range	61.41 - 65.53
52-Week Range	35.17 - 68.58
Beta	2.37

About RYTM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RYTM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RYTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Rhythm Pharmaceuticals has released their quartely earnings on May 7, 2025:

Revenue of $32.7M misses estimates by $8M, with 25.94% YoY growth.

EPS of -0.81 misses estimates by -0.13, with 65.53% YoY growth.

Next Earnings Release

Rhythm Pharmaceuticals Inc. is scheduled to release its earnings on May 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 weeks ago

+5.04%

Rhythm Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

1 month ago

+17.06%

Rhythm Pharmaceuticals shares are trading higher after the company announced that the Phase 3 TRANSCEND trial met its primary endpoint.

News

22 hours ago · seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

16 hours ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago.

1 week ago · zacks.com

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · zacks.com

Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?

Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

4 weeks ago · seekingalpha.com

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmel...

1 month ago · zacks.com

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.

4 weeks ago · zacks.com

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

1 month ago · reuters.com

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.

2 months ago · seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Me...

2 months ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.70 per share a year ago.

Load More News